Australian pharma company Starpharma Holdings Ltd. (SPL.AX) Monday announced that the US Food and Drug Administration or FDA did not approve VivaGel, a treatment for Bacterial vaginosis (BV), and sought additional clinical efficacy data.As per the company, it has already been approved in more than 45 countries globally to treat BV.Presently VivaGel's New Drug application remains open and the firm is not planning to pursue additional clinical studies at this time.Today, Starpharma shares closed at AUD 0.135, down 6.89% in Australia.

澳大利亚制药公司Starpharma Holdings Ltd.（SPL.AX）周一宣布，美国食品和药物管理局（FDA）未批准用于治疗细菌性阴道病（BV）的VivaGel，并寻求其他临床疗效数据。据该公司称，它已在全球45多个国家获得批准用于治疗BV。目前，VivaGel的新药申请仍在开放中，该公司目前不打算进行额外的临床研究。今天，Starpharma股价收于0.135澳元，在澳大利亚下跌6.89%。

For comments and feedback contact: editorial@rttnews.comBusiness News.

如需评论和反馈，请联系：editorial@rttnews.comBusiness新闻。

Biotech Stocks Facing FDA Decision In November 2023

2023年11月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision In October 2023

2023年10月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision in August 2023

2023年8月美国食品和药物管理局决定生物技术股